U.S.S.N. 08/444,934 Filed: May 22, 1995 AMENDMENT

APPENDIX: Clean Copy of Claims

11

4. (five times amended) Purified human tissue factor fragment expressed from a nucleotide molecule encoding a tissue factor selected from the group consisting of tissue factor having an amino acid sequence as provided in Figure 2 from at least amino acid residue one to at least amino acid residue 219, and human tissue factor having an amino acid sequence as provided in Figure 2 from at least amino acid residue one to at least amino acid residue 219 wherein an amino acid residue at an N- or O-glycosylation site is substituted, wherein the tissue factor has activity in a clotting assay with human plasma.



5. (twice amended) The tissue factor fragment of claim 4 wherein the nucleotide molecule does not encode the transmembrane domain defined by amino acids 220 to 243 as provided in Figure 2.



6. (four times amended) The tissue factor fragment of claim 4 wherein the nucleotide molecule encodes a tissue factor having an amino acid sequence as provided in Figure 2 from amino acid residue one to amino acid residue 219.



8. (four times amended) The tissue factor fragment of claim 4 expressed in a recombinant non-human host cell.



20. (four times amended) A soluble isolated tissue factor fragment expressed from a nucleotide molecule encoding tissue factor in a recombinant non-human host cell, the tissue factor having the amino acid sequence shown in Figure 2 from amino acid one to an amino acid

U.S.S.N. 08/444,934 Filed: May 22, 1995 AMENDMENT

Towlede

residue between amino acid residues 219 and amino acid residue 263, wherein the tissue factor has activity in a clotting assay.

- 21. (amended) The tissue factor fragment of claim 20 which is not glycosylated.
- 23. (amended) The tissue factor fragment of claim 20 having an amino acid sequence of Figure 2 from between amino acid one and between residues 220 and 263.

24. (twice amended) The tissue factor fragment of claim 20 wherein the cysteine residues are substituted with other amino acids.

- 25. (twice amended) The tissue factor fragment of claim 20 wherein the potential proteolysis sites are deleted by replacing the amino acids with glutaminyl or histidyl residues or deleting one of the basic residues.
- 27. (twice amended) The human tissue factor fragment of claim 20 expressed in a host cell selected from the group consisting of procaryotic cells, non-human animal cells, insect cells, plant cells, and yeast, having activity in a clotting assay.
 - 28. (amended) The human tissue factor fragment of claim 27 which is not glycosylated.
- 31. (amended) Recombinant human tissue factor fragment expressed from a nucleotide sequence encoding an amino acid sequence comprising from amino acid residue one to amino acid residue 219 as provided in Figure 2, wherein the tissue factor protein has activity in a clotting assay with human plasma.
- 32. (amended) The recombinant human tissue factor fragment of claim 31 wherein the nucleotide sequence does not encode the transmembrane domain of human tissue factor.

MSM 101 CONTC 079307/0000B U.S.S.N. 08/444,934 Filed: May 22, 1995 AMENDMENT

- 33. (amended) The recombinant human tissue factor fragment of claim 32 wherein the nucleotide sequence does not encode the amino acid sequence from amino acid residue 220 to amino acid residue 243 as provided in Figure 2.
- 34. (amended) The recombinant human tissue factor fragment of claim 31 which is not glycosylated.
- 1 11 molde 35. (amended) The recombinant human tissue factor fragment of claim 31 which is expressed in a host cell selected from the group consisting of procaryotic cells, non-human animal cells, insect cells, plant cells, and yeast.
 - 36. (amended) The recombinant human tissue factor fragment of claim 31 which includes an heterologous amino or carboxyl terminal fusion.
 - 38. (amended) The recombinant tissue factor fragment of claim 31 wherein the cysteine residues are substituted with other amino acids.
 - 39. (amended) The recombinant tissue factor fragment of claim 31 wherein the potential proteolysis sites are deleted by replacing the amino acids with glutaminyl or histidyl residues or deleting one of the basic residues.
 - 40. (amended) The recombinant tissue factor fragment of claim 31 wherein a residue at an N- or O-glycosylation site is substituted or deleted.
 - 41. (amended) Recombinant human tissue factor fragment comprising an amino acid sequence from amino acid residue one to amino acid residue 219 as provided in Figure 2, wherein the tissue factor protein has activity in a clotting assay with human plasma.